Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in addition to cobimetinib and vemurafenib for BRAF mutated metastatic melanoma Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) , Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204) Melanoma Skin Cancer 2019 View  |  Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Melanoma Skin Cancer 2018 View  |  Download
Bempegaldesleukin in combination with nivolumab for previously untreated unresectable or metastatic melanoma Bempegaldesleukin (NKTR-214; BMS-986321; NEKTAR) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2022 View  |  Download
Bifikafusp alfa-onfekafusp alfa neoadjuvant therapy for treating resectable stage IIIB and IIIC melanoma Daromun Melanoma Skin Cancer 2023 View  |  Download
Dabrafenib with trametinib for treating metastatic or unresectable BRAF V600 mutation-positive melanoma in adolescents Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2023 View  |  Download
Dabrafenib with Trametinib with adjuvant therapy for treating advanced BRAF V600 mutation-positive melanoma in adolescents Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2023 View  |  Download
Lifileucel for unresectable or metastatic melanoma – second-line or greater Lifileucel (Contego; LN-144) IB Melanoma Skin Cancer 2020 View  |  Download
Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2017 View  |  Download
Nivolumab adjuvant for treating for stage IIB/IIC resected melanoma Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2022 View  |  Download
Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3) Melanoma Skin Cancer 2019 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications